GUIDE / ROUTE: IV + INJECTION · UNAPPROVED-COMPOUNDED
NAD IV Therapy: What the Research Shows About Infusions and Injectable Routes
Infused NAD+ raises plasma NAD+ briefly, then clears within hours. The controlled evidence is the weakest of any route, and compounded injectables carry documented quality risk. Documented here as an unapproved compounded therapy, not an offer.
The short version
Here is NAD IV therapy in plain terms. An IV drip (or a shot) puts NAD+ (a fuel-handling helper molecule every cell uses) straight into your blood, skipping the gut. That sounds efficient, but two facts shape everything: the body clears infused NAD+ from the blood within a couple of hours, and these preparations are compounded — mixed by a pharmacy, not approved by the FDA, and at least one batch was recalled for contamination [10][11]. The strongest human evidence for raising NAD+ is actually for swallowed precursors (building blocks like NMN and NR), not for the drip. This page lays out why, with sources.
Read this first
CAUTION — UNAPPROVED, COMPOUNDED ROUTE. NAD IV therapy delivers NAD+ straight into the bloodstream in a wellness or clinical setting. It is a compounded preparation, not an FDA-approved drug, and the controlled evidence behind it is thin. Infused NAD+ does raise blood NAD+ — but only briefly, clearing from plasma within about two hours [10]. Compounded injectables have also carried a real quality risk: the FDA issued a Class I recall (its most serious tier) of a compounded NAD+ injection for elevated bacterial endotoxin [11]. This page documents what is known and what is missing about the injectable routes. It gives no dosing or timing instructions and sells nothing.
How long NAD+ persists: infused clearance vs precursor elevation
The pharmacokinetics (how the body absorbs and clears a substance) are the heart of the IV question. NAD+ itself is not freely taken up intact by most cells, and infused NAD+ is rapidly cleared: a pilot pharmacokinetic study using a continuous infusion found near-complete removal from plasma within roughly the first two hours [10]. Contrast that with oral precursors, which raise whole-blood NAD+ over days to weeks, with the elevation sustained through chronic 8–12 week dosing [4][3]. So an infusion produces a sharp, short spike; precursor capsules produce a slower, durable rise. This is the NAD+ half life picture in one line: infused NAD+ is gone from plasma in about two hours, while oral-precursor blood-NAD+ elevation persists for as long as dosing continues [10][4]. The practical implication is that the high plasma NAD+ an infusion produces is transient by design — the molecule does not linger the way a precursor-driven rise does.
Injectable and IV NAD+: pharmacokinetics and quality risk
Beyond IV infusion, NAD+ is also given by subcutaneous and intramuscular injection in compounded form, with minimal peer-reviewed pharmacokinetic data for those routes. Reported wellness-clinic infusion protocols run roughly 250–1000 mg per session over several hours; one formal pharmacokinetic study used a 3 µmol/min continuous infusion over six hours [10]. The slow infusion rate is itself telling — pushing NAD+ in faster is what tends to provoke the flushing, nausea, and chest or abdominal discomfort reported with the route, so protocols stretch the dose over hours to keep it tolerable [10]. The quality concern is concrete, not theoretical: NAD+ and its precursors are hygroscopic and degrade with heat and moisture, reconstituted injectable NAD+ must be kept cold and protected from light, and compounded injectables carry contamination and endotoxin risk — the basis for the FDA Class I recall already noted [11]. A Class I designation is the FDA's most serious recall tier, reserved for products with a reasonable probability of serious harm. None of these injectable routes is FDA-approved.
Does NAD IV actually work?
IV NAD+ has the weakest controlled evidence of any route. It reliably raises plasma NAD+ briefly, but that NAD+ is cleared within hours [10], and benefits for clinical outcomes are not established in rigorous trials — most available data are pilot or retrospective. By contrast, the controlled human data sit with oral precursors: NR and NMN raise blood NAD+ dose-dependently and improved metabolic and physical-performance endpoints in randomized trials [4][1][15]. Where you want controlled evidence, it is on the oral side, not the infusion side.
What is an NAD injection?
An NAD injection or IV infusion delivers NAD+ directly into the bloodstream in a wellness or clinical setting. It is a compounded, not FDA-approved, therapy with limited controlled evidence, and infused NAD+ is rapidly cleared from plasma within about two hours [10]. Subcutaneous and intramuscular injection forms exist but have minimal peer-reviewed pharmacokinetic data [11].
Is NAD+ shot worth it?
Controlled evidence for injectable or IV NAD+ is weak; most data are pilot or retrospective, and infused NAD+ leaves plasma within about two hours [10]. Stronger controlled human data exist for oral precursors — NMN and NR — than for any shot or infusion [3][4]. This digest describes what studies measured and makes no recommendation.
When should you inject NAD+?
There is no established, evidence-based timing for injectable NAD+; protocols vary by wellness clinic and are not standardized in the peer-reviewed literature. This page documents what studies measured — chiefly rapid plasma clearance after infusion [10] — and gives no dosing or timing instructions.